Abstract: Polyelectrolyte multilayer (PEM) films, established by layer-by-layer deposition, are attractive for drug delivery systems as drug delivery can be systematically controlled. However, one limitation of this coating method is the time-consuming character. The adsorption time of one layer typically takes minutes and commonly, investigated multilayers loaded with drugs contain more than 80 layers. Within our study we systematically evaluate parameters allowing the generation of a PEM-based drug delivery system on poly(L-lactide) (PLLA) with a reduced time consuming construction process and a controlled delivery of physiological amounts of active drugs. Therefore, several PEM based on PLLA with only five tetralayers consisting of polycation/polyanion/drug/polyanion are established and investigated regarding the release profiles of avidin fluorescein isothiocyanate as model substance and vascular endothelial growth factor (VEGF). We demonstrate that the polyelectrolyte nature and molecular weight of polyanions (hyaluronic acid, polyacrylic acid) and polycations (poly-L-lysine, chitosan) strongly influence the drug release profiles. Furthermore, in vitro cell culture studies show that the released VEGF amount and the cover layer from the favorite coating systems can beneficially enhance human umbilical vein endothelial cell (HUVEC) proliferation.
Introduction
Tissue engineering using biodegradable materials for the provision of surfaces that promote the regeneration and reconstruction of human organs has emerged as a promising alternative approach for the replacement of dysfunctional organs. Applied biomaterials should be both biodegradable and bioactive [1] . Besides several other biodegradable polymers, poly(L-lactide) (PLLA) has already been successfully used as scaffold material and as matrix for local drug delivery (LDD) systems due to its good mechanical and manufacturing properties, as well as its moderate biocompatibility [2, 3] .
However, the biomedical applications of PLLA, especially the abilities to promote cell adhesion, proliferation, and to maintain normal cell phenotype and functions are limited by its low wettability, which can lead to a foreign body response and uncontrolled fibrotic encapsulation initiated by nonspecific adsorption of serum proteins. In order to overcome these limitations a promising approach is the surface modification of polymers [4, 5] .
Besides wet-and plasma-chemical surface modifications [6, 7] , the deposition of thin coatings via Layer-byLayer (LbL) technique, introduced by Decher et al. in 1992 [8] [9] [10] , has become a facile, inexpensive, and environmentally friendly method for the modification of widespread applications ranging from energy and electrochemical devices to biomaterials [11] . Typically, the LbL deposition is based on the sequential adsorption of polyelectrolytes with complementary functional groups employing electrostatic interactions, hydrogen bonding, and/or covalent interactions. LbL is unique in its ability to incorporate high concentrations of biologic drugs for controlled local delivery using room temperature and mild aqueous conditions that preserve fragile protein activity [12] .
In particular, recent advances in LbL-based drug delivery include among others [13] [14] [15] the direct integration of polyionic drugs within a polyelectrolyte template. For instance, Hammond et al. constructed a multilayer with different numbers of tetralayers (20-100) of poly (β-amino-esters) (P2) and chondroitin sulfate (chondroitin) as well as bone morphogenetic protein 2 (BMP-2, IEP = 8.5) as poly-ionic drug on a Therics™ poly (ε-caprolactone)/β-tricalcium phosphate (PCL/BTCP) printed scaffold. It has been reported that the BMP-2 amount is completely released from [P2/chondroitin/BMP-2/chondroitin] 100 within 2 weeks and the released BMP-2 retains its ability to induce bone differentiation in MC3T3 E1S4 preosteoblasts [16] . Furthermore, Shah et al. described a multilayer composition with dual loading of BMP-2 and vascular endothelial growth factor (VEGF) on the same PCL/ BTCP scaffolds. They show that the polyelectrolyte multilayer films are able to independently deliver physiological amounts of active BMP-2 and VEGF over different timeframes inducing a corresponding dose response [17] .
Thus, drug release and load can be precisely controlled by the architecture of the multilayer film, allowing compartmentalization resulting in sequential drug release, and the number of layers incorporated, respectively [18] .
However, the fundamental drawback of the LbLmethod is still the time-consuming character. The adsorption time of one layer typically takes several minutes and may vary with the nature of polyelectrolytes. Commonly, multilayers loaded with active agents were investigated with a number of layers more than 80. Until today, this limitation has never been properly addressed with the perspective of scale up.
Therefore this study aims to develop and systematically evaluate parameters allowing the generation of a polyelectrolytmultilayer-PEM-based drug delivery system on PLLA with a reduced time consuming construction process.
The PEM coating was realized via a tetralayer (TL) structure composed of four alternating single layers based on well established polyelectrolytes for biomedical applications [19] [20] [21] [22] , such as poly(L-lysin) (PLL) and chitosan as polycations and polyacrylic acid (PAA) and hyaluronic acid (HA) as polyanions. With the purpose of maximizing drug load and thereby minimizing construction time, the influence of the polyelectrolyte nature and molecular weight were considered regarding achievable drug loads at a reduced TL amount of five. Moreover, this systematic investigation should give general implications concerning the choice of polyelectrolytes for the build-up of PEM. For this screening, avidin-FITC was chosen, as model poly-cationic drug at physiological pH, due to its easy detectability, high availability, and the basic isoelectric point of about 10.5.
The resulting favourite LDD-system was further investigated using vascular endothelial growth factor (VEGF) as poly-ionic drug (IEP = 8.5). VEGF is known to selectively promote cell adhesion and proliferation of HUVECS. The release behavior and the cell compatibility of the functional multilayer films were characterized in vitro.
Results
We chose PLLA which is a biodegradable aliphatic polyester and has been extensively studied and applied in several medical applications [2, 18, 19] , as substrate for a local drug delivery system based on polyelectrolytes. In order to facilitate the deposition of polyelectrolytes to PLLA surfaces by layer-by-layer (LBL) self-assembly, polar groups including hydroxyl, carboxyl and other oxygen functional groups were introduced to the surface using O 2 plasma treatment. Due to the acidic character of the resulting polar groups on the surface, PLLA can then serve as polyanionic substrate. Subsequently, the polycation PLL (IEP = 9.74) or chitosan of different molecular weight [chitosan low (Mw < 120,000 g/mol), chitosan medium (Mw < 150,000 g/mol) and chitosan high (Mw < 220,000 g/mol)], followed by the polyanion PAA (IEP = 4.2) or HA followed by the polycationic model drug avidin-FITC (IEP = 10.5), could be deposited. With the purpose of maximizing drug load, a suitable polyanion was screened followed by a selection of an appropriate polycation. Therefore, the following PEM designs PLLA(PLL/PAA/avidin-FITC/ PAA) 5 , PLLA (PLL/HA/avidin-FITC/HA) 5 . and PLLA (chitosan/PAA/avidin-FITC/PAA) 5 including chitosans of different molecular weight were examined in closer detail.
Characterization of deposited PEM
All established PEM were characterized via contact angle measurements, scanning electron microscopy (SEM) and fluorescence microscopy.
Periodic oscillations in contact angle values of the outermost layer were detected along the PEM constructions process. Interestingly, the same polyelectrolyte layer shows different contact angle dependent on the layer underneath ( Figure 1 ). The negatively charged PAA or HA have a lower contact angle in comparison to the used polycations PLL and chitosan low .
Besides the contact angle the surface morphology differs for the three investigated PEM systems. The surface In order to get an idea about the incorporated avidin-FITC amount besides the surface morphology, the PEM systems were examined via fluorescence microscopy. The fluorescence images show higher intensity for the PLL/PAA system ( Figure 3A ) than the PLL/HA system ( Figure 3B ). In view of the different used polycations PLL, chitosan low and chitosan high the fluorescence images show rather similar intensity for the investigated PEM films ( Figure 3A ,C,D).
In vitro drug release in function of the polyelectrolyte nature and the molecular weight
The PAA system released a much higher amount of avidin-FITC than the HA system ( Figure 4 ). Both investigated PEM systems using different polycations release avidin-FITC in a similar range, as shown in Figure 4 . PLLA (chitosan low / PAA/Avi-FITC/PAA) 5 released slightly more avidin-FITC with 0.78 μg after ~3 days compared to PLLA(PLL/PAA/ Avi-FITC/PAA) 5 with 0.73 μg after 3 days. Due to the promising results using the PAA-system, in contrast to HA, PAA is used for further investigations as polyanion.
Both used polycations, chitosan low and PLL, are already successfully described in literature [20] [21] [22] . However, since chitosan is naturally occurring, more biocompatible, and avidin-FITC release is slightly higher, the PLLA(chitosan low /PAA/Avi-FITC/PAA) 5 was favoured for further investigations.
Besides the kind of the applied polyelectrolytes, the molecular mass of the polymer influences drug release. Hence, in vitro release studies of PEM using chitosan as polycation with different molecular masses were carried out. In this case, chitosan low (Mw < 120,000 g/mol), chitosan medium (Mw < 150,000 g/mol) and chitosan high (Mw < 220,000 g/mol), as alternating polycation, were investigated. Figure 4 shows the corresponding avidin-FITC release profiles at pH 7.4 and 37°C. Within 12 h we observed a burst drug release followed of a slower release phase. An increasing molecular mass is associated with a simultaneously increased release of avidin-FITC.
Out of the investigations, the resulting favourite PEM film is based on PLLA covered with chitosan high and PAA layers. Due to the fact that the cover layer of the multilayered films is suspected to have an important influence on the cell adhesion, the systems PLLA (chitosan high /PAA/ drug/PAA) 5 and PLLA (chitosan high /PAA/drug/PAA) 5 -chitosan high were further analysed.
In vitro VEGF release
Related to the desired medical application of these PEM films, VEGF was used as embedded model drug for the in vitro release studies instead of avidin-FITC. Therefore the systems PLLA (chitosan high /PAA/VEGF/PAA) 5 (chitosan high /PAA/VEGF/PAA) 5 -chitosan high were further analysed. Figure 5 shows VEGF release regarding the impact of the additional cover layer. Both systems are following an initial burst release of VEGF. It seems that the cover layer has no significant influence on the VEGF release. The VEGF release is rather similar for both. Within the first 4 days around 13 ng were released.
In vitro cell studies
In order to examine the influence of the surface modifications and the embedded growth factor VEGF on viability and proliferation of HUVECs and HCASMCs, we conducted in vitro studies in direct contact with PLLA (chitosan high /PAA/drug/ PAA) 5 and PLLA (chitosan high /PAA/drug/PAA) 5 chitosan high with and without VEGF. All investigated surface modifications of PLLA did not influence cell viability of both, HUVECs and HCASMCs (data not shown). However, the multilayer coating on PLLA using PAA and chitosan high did significantly influence proliferation of HUVECs ( Figure 6A ). While chitosan high significantly increased HUVEC proliferation ( Figure 6A ; p = 0.0005 compared to PLLA and p = 0.0001 compared to HCASMC), proliferation of HCASMCs was not influenced by PAA or chitosan high coupling. Additional loading of VEGF to the PLLA-(chitosan high / PAA/drug/PAA) 5 surface further enhanced HUVEC proliferation ( Figure 6A ; p = 0.0001 and p = 0.01, respectively) compared to the respective polymer surface without VEGF. On PLLA (chitosan high /PAA/drug/PAA) 5 chitosan high surfaces no changes in cell growth due to VEGF were observed. Furthermore, VEGF-loading did not affect HCASMC growth as well (data not shown). 
Discussion
The biomedical applications of biodegradable polyesters, especially the abilities to promote cell adhesion, proliferation, and to maintain normal cell phenotype and functions are often hampered to a certain extent by their low wettability and the lack of bioactive groups. Therefore surface modifications of polymeric materials are necessary for improvement of cell-scaffold interactions. In this investigation the LbL deposition technique was used to generate a multi-layered drug delivery coating, improving the cell-scaffold interaction on the surface of PLLA. The LbL offers several advantages in comparison to thin film deposition methods, such as the use of a wide range of polyelectrolytes allowing precise control of drug release [8] . Furthermore this technique provides the possibility to increase the hydrophilicity of arbitrarily shaped substrate surface and to simultaneously immobilize several active agents such as growth factors or anti-inflammatory drugs [17, 23] for the promotion of wound healing. Due to the fact that the LbL deposition is based on the consecutive adsorption of polyanions and polycations via electrostatic interactions on a charged substrate, the investigated relative inert PLLA surface was activated via oxygen plasma beforehand [10] . Here, different PEM systems PLLA(PLL/ PAA/avidin-FITC/PAA) 5 , PLLA (PLL/HA/avidin-FITC/HA) 5 and PLLA (chitosan/PAA/avidin-FITC/PAA) 5 were established on PLLA. The applied polyanions, PAA and HA, and polycations, chitosan and PLL were considered due to their previous described promising properties such as biocompatibility and biodegradability for the use in biomedical applications [24, 25] . Moreover, the choice allows for a systematic investigation of the influence of nature and properties (charge density, molecular weight) of polyelectrolytes on achievable drug loads.
Prior to drug release, all established PEM were thoroughly characterized via contact angle measurements, scanning electron and fluorescence microscopy. The observed periodic oscillations in contact angle values for all investigated PEM films seem to be a function of the nature/charge of the outermost layer. Multilayer structure terminated with a PLL, chitosan low or avidin-FITC layer are more hydrophobic than ones terminated with PAA or HA. However, the same outermost layer did not present the same contact angle. It may be caused by the layer interpenetration between neighbouring PAA and chitosan films where the segments of the underlying layer are able to influence the surface hydrophilicity [26] . Theoretical modelling predicts that diffusion of the polyelectrolyte in and out of the film is strongly related to the concentration of "fixed" charges (i.e. uncompensated polycation/polyanion pair charges) within the multilayer and controlled by the difference between its chemical potential within the multilayer and in the aqueous phase. Therefore, most probably the investigated PEM-systems are following an "exponential growth" of layers [27] . The surface roughness seems to be depending on the used polycation. The surface of the PLL system is more structured than the chitosan system.
Next to the importance of surface properties the amount of incorporated drug is essential for biomedical application. The different fluorescent intensities of avidin-FITC is most probably caused by the fact that the films constructed with PAA is yielding more ionically crosslinked films related to HA, as PAA exhibits a higher charge density resulting in a higher interaction between avidin-FITC and PAA [17] . The negligible influence of the applied polycations on the fluorescent intensity may be caused by the lack of direct contact with avidin-FITC.
These results were confirmed by the in vitro release studies of avidin-FITC, both polycation PEM systems show similar released amounts while PEM systems using PAA released much more avidin-FITC than PEM systems using HA. In contrast to the marginal influence of the polycation kind on the avidin-FITC release, the molecular weight of the polycations seems partly to control the incorporated drug amount and their release. With increased molecular weight of chitosan the released amount of avidin-FITC increased as well. Most probably, the polymer chains of chitosan containing higher molecular weight simply spread out to occupy more area on the polymer surface, thus more area are available for the diffusion of the following layers resulting in thicker layer. Moreover, maybe due to the longer high molecular polymer chains containing more charges, a high amount of charges is needed to neutralize the surface charges of the multilayer and to create sufficient new charges for the further build-up [27] [28] [29] . Both possible effects result in a higher incorporated avidin-FITC amount.
Next to the systematic investigation of the influence of nature and properties of polyelectrolytes another aim was to generate a PEM-based drug delivery system on PLLA with a reduced time consuming construction process. Therefore the in vitro drug release from PEM systems with various amounts of TL (1 corresponding to 35 min, 5-3 h and 10-6 h construction time was evaluated in a previous study (data not shown). The screened release profiles show that with increased TL number the released drug amount and the initial drug release increase. However, by comparison of the time consumption of the construction process with the released drug amount it was ascertained that the favoured PEM multilayer system with only 5 TL allows the delivery of amounts of active VEGF relevant for proliferative effects on HUVECS, according to our former investigations [30] . In contrast to other described drug delivery PEM systems such as from Hammond et al. with 20-100 TL and construction time of 12-60 h [16] or from Shah et al; with 40-120 TL and a construction time of 20-60 h [17] , we were able to establish a PEM system containing active relevant VEGF amounts with reduced time consumption.
The favored PEM system PLLA(chitosan high /PAA/ drug/PAA) 5 was further investigated in view of the important cell-implant-interaction for biomedical application. Therefore, the cover layer was varied using PAA or chitosan high. Interestingly, the released amount of VEGF was only marginal different.
However, while the VEGF-release seemed independent on the present cover layer, we show a significant influence on endothelial cell proliferation. While HUVEC growth is not influenced on PEM with PAA as cover layer, HUVEC show a 2.3-fold increase in proliferation ( Figure 6A ) on PEM with chitosan as cover layer in comparison to unmodified PLLA. Interestingly, HCASMC growth is not considerably altered. Furthermore, we show that VEGF-loading significant improved the properties of unmodified and PEM-modified PLLA with PAA as cover layer ( Figure 6B ) by further increasing HUVEC proliferation. In contrast, VEGF did not show any additional effect on HUVEC growth when released from PEM with chitosan as cover layer. We assume that the surface of the PEM with chitosan as cover layer is already confluently seeded with HUVEC. Thus, the influence of VEGF is only marginally visible. However, further studies are required to determine the reasons for the minor influence of VEGF on HUVEC growth.
In summary, the layer-by-layer assembly technique is successfully employed to construct chitosan/PAA multilayers on O 2 -activated PLLA surfaces. The oscillation of contact angle between even and odd layers and the fluorescent results have confirmed that the multilayers are constructed in a LBL manner. The in vitro cell culture studies show that the released VEGF amount and the terminated layer can beneficially influence the HUVECs while not altering HCASMC proliferation. Therefore, the investigations show that it seems possible to construct a multilayer system on PLLA with only 5 TL (chitosan/PAA/ VEGF/chitosan) containing physiological amounts of VEGF in a reduced time interval. Besides that, an essential advantage of the here investigated PEM systems is the applicability for several biomedical applications by only changing the incorporated drug.
Materials and methods

Materials
All chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany), Mallinckrodt Baker (Griesheim, Germany), SERVA Feinbiochemica (Heidelberg, Germany), Thermo Scientific (Karlsruhe, Germany) or Merck (Darmstadt, Germany) in p.a. quality or higher.
Cell culture
Human umbilical vein endothelial cells (HUVEC) were obtained from collagenase type II (Biochrom, Berlin, Germany) digested umbilical cords and cultivated as described previously [31] . Primary cultures of human coronary artery smooth muscle cells (HCASMC) were purchased from Provitro GmbH (Berlin, Germany). Cells were obtained at passage 2 and cultured in smooth muscle cell growth medium (Provitro GmbH, Berlin, Germany) supplemented with 10% Fetal Bovine Serum (FBS, Invitrogen, Carlsbad, CA, USA). The used cell culture medium for the in vitro studies are supplemented with
Film fabrication
As model biodegradable polymer for polyelectrolyte multilayer modification, poly-L-lactide (PLLA, Resomer L210, Boehringer Ingelheim, Germany) was used.
The polymer films for in vitro studies were prepared via dipcoating: Therefore, 2.6 g PLLA was dissolved in 100 mL chloroform. Then an immersed body (plummet) was dipped into the polymer solution 16 times for 5 min. After drying for 24 h and cutting off from the plummet, the resulting PLLA films were washed in methanol and distilled water for 2 days and dried for 7 days in a vacuum cabinet drier at 80°C and 40 mbar. The film thickness was analyzed by means of a thickness gauge (2109 Mitutoyo, Mitutoyo Europe GmbH, Neuss, Germany) and with around 100 μm.
Plasma-chemical activation
In order to generate a negatively charged PLLA surface in preparation for polyelectrolyte deposition, samples were treated with a plasma etching (PE) electrode in an oxygen (O 2 ) radio frequency (RF) plasma generator (frequency 13.56 MHz, power 100 W, Diener electronic GmbH & Co. KG, Ebhausen, Germany) at a low pressure of 0.3 mbar for 5 min.
Deposition of polyelectrolyte multilayers
The polyelectrolyte multilayer (PEM) films were fabricated according to Shah et al. [17] via a dip-coating robot (KSV Nima, Espoo, Finland) with the following dipping protocol: The activated PLLA sample was dipped 5 min in poly (L-lysine) (PLL) or chitosan (containing different molecular weight chitosan low (Mw < 120,000 g/mol), chitosan medium (Mw < 150,000 g/mol) and chitosan high (Mw < 220,000 g/mol)) solution as polycation (2 mg/mL in 25 mM sodium acetate buffer pH 5.0), washed three times in 25 mM sodium acetate buffer pH 5.0 (10, 20, 30 s), dipped 5 min in polyacrylic acid (PAA) and hyaluronic acid (HA) solution as polyanion (2 mg/mL in 100 mM sodium acetate buffer pH 5.0) and again washed 3 times in 100 mM sodium acetate buffer pH 5.0 (10, 20, 30 s). Subsequently, the coated film was dipped 10 min in avidin-FITC (40 μg/mL) or VEGF (2 μg/mL) in 25 mM sodiumacetate buffer pH 5.0, washed once (10 s) in, 25 mM sodiumacetate buffer pH 5.0, dipped 5 min in PAA or HA and finally washed three timed in 25 mM sodium acetate buffer pH 5.0 (10, 20, 30 s). This protocol was performed once or repeated five times to achieve the deposition of 1 or 5 TL, respectively. The resulting deposited films were allowed to dry for 48 h at 4°C. Next, VEGF 165 containing films were fabricated on PLLA using the same dipping protocol to achieve 5 TL. Each step of LbL process was verified via contact angle measurements by sessile drop method (Contact Angle System, OCA 20, Dataphysics Instruments GmbH, Filderstadt, Germany) and the morphological changes were examined in a XL30 (Philips, Eindhoven, The Netherlands) scanning electron microscope. Microscopic pictures of avidin-FITC-loaded PEM systems were obtained using a Fluoview FV1000 (Olympus, Hamburg, Germany) system. The contact angles were analyzed using Excel. Mean values and standard deviations were calculated from 10 samples with n = 2 measurements per sample.
In vitro avidin-FITC release
The in vitro avidin-FITC release from PEM containing PLLA foils (Ø = 6 mm) was performed in 350 μL cell culture medium (pH 7.4) at 37°C with gentle shaken. The medium was removed and replaced by fresh solution in certain intervals. In order to quantify the released avidin-FITC amount, the removed medium was analyzed using a FLUOstar Optima (BMG Labtech, Offenburg, Germany) plate reader. The calibration curve was prepared in the concentration range 2.5-0.002 μg/mL, and measured with excitation at 495 nm and emission at 525 nm. The used cell culture medium for the in vitro studies are consists of MCDB131 (PAN Biotech, Aidenbach, Germany) with 2.5% fetal calf serum, 100 U/mL penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine.
In vitro VEGF release
The in vitro release of VEGF from the investigated PEM (Ø = 6 mm) in 350 μL cell culture medium (pH 7.4) at 37°C was measured by means of ELISA (human VEGF ELISA Kit RayBio ® , Hölzel Diagnostika, Köln, Germany). The ELISA was carried out as described in the instruction manual of the ELISA VEGF Kit. The used cell culture medium for the in vitro studies are consists of MCDB131 (PAN Biotech, Aidenbach, Germany) with 2.5% fetal calf serum, 100 U/mL penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine.
Biocompatibility assays
Cell viability was assessed utilizing an AlamarBlue ® (Biosource, Camarillo, CA) cell viability assay. Endothelial and smooth muscle cells were seeded onto Ø 5 mm polymer cover slips at a density of 6.000 cells per 96-well, matched to untreated controls, and cultured for 6 days at 37°C with 5% CO 2 and 95% humidity. Subsequently, AlamarBlue ® was added to each well as 10% of the sample volume and cells were incubated for 16 h. The resulting fluorescence was read on a Synergy™H1 microplate reader (BioTek Instruments, Bad Friedrichshall, Germany) using an excitation wavelength of 570 nm and an emission wavelength at 585 nm.
Relative cell proliferation was quantified using a Cell Proliferation ELISA, BrdU (Roche, Mannheim). Endothelial and smooth muscle cells were seeded at a density of 6.000 cells/96-well on polymer cover slips with a diameter of 5 mm and cultured for 6 days in black 96-well MPs with flat, clear bottom. According to manufacturers' instructions, 100 μM BrdU was added to each well and incubated for 24 h at 37°C, 5% CO 2 and 95% humidity. Cell proliferation was determined using a multimode microplate reader Synergy™H (BioTek Instruments, Bad Friedrichshall, Germany).
Further analyzing methods
Viability and proliferation experiments were repeated at least four times. Data were analysed using GraphPad Prism© 5 software (La Jolla, CA, USA). Statistical differences between groups were analysed using a non-parametric two-tailed Mann-Whitney U-test. Unless otherwise stated, p < 0.05 was defined as statistically significant.
